November 27, 2019 Regulatory InDex Pharmaceuticals Holding AB (publ) interim report January – September 2019 Read more
October 9, 2019 Regulatory Bulletin from Extraordinary General Meeting in InDex Pharmaceuticals Holding AB (publ) Read more
September 19, 2019 Regulatory Notice of Extraordinary General Meeting in InDex Pharmaceuticals Holding AB (publ) Read more
September 19, 2019 Regulatory InDex Pharmaceuticals has completed a directed share issue of approximately SEK 140 million (USD 14 million) Read more
September 19, 2019 Regulatory InDex Pharmaceuticals announces intention of a directed share issue Read more
August 27, 2019 Regulatory InDex Pharmaceuticals meets primary endpoint in the phase IIb study CONDUCT with cobitolimod in ulcerative colitis Read more
August 15, 2019 Regulatory InDex Pharmaceuticals Holding AB (publ) interim report January – June 2019 Read more
June 26, 2019 Regulatory InDex Pharmaceuticals enrolls last patient in phase IIb study CONDUCT with cobitolimod Read more
May 6, 2019 Regulatory Bulletin from Annual General Meeting in InDex Pharmaceuticals Holding AB (publ) Read more
May 6, 2019 Regulatory InDex Pharmaceuticals Holding AB (publ) interim report January – March 2019 Read more
April 11, 2019 Regulatory InDex Pharmaceuticals provides status update on the patient recruitment in the CONDUCT study Read more
April 5, 2019 Regulatory Notice of Annual General Meeting in InDex Pharmaceuticals Holding AB (publ) Read more
April 2, 2019 Regulatory InDex Pharmaceuticals Holding AB (publ) publishes Annual Report for 2018 Read more